November 2021: Nedávno sa začala prvá klinická skúška domácej terapie chimérickým antigénovým receptorom T (CAR-T) novej generácie v Južnej Kórei, ktorá je navrhnutá tak, aby obchádzala signály kontrolných bodov imunity.
Kórejský pokročilý inštitút vedy a technológie (KAIST) v stredu oznámil, že klinická štúdia fázy 1b jeho bunkovej terapie CAR-T v súčasnosti prebieha v Samsung Medical Center v Soule. Skúška sa vykonáva s 10 kórejskými pacientmi, ktorí majú recidivujúci a refraktérny difúzny veľkobunkový B lymfóm. Marketingové práva na plynovod prešli z univerzity na spoločnosť Curocell, ktorú spoluzakladal profesor Kim Chan-hyuk. Curocell má na starosti klinický vývojový program revolucionára imunoterapia.
In addition, a Phase 2 Klinická štúdia involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for chimérický antigénový receptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Možno si prečítate: CAR T-bunková terapia v Kórei
Zistenia štúdie boli prezentované v článku, ktorý bol publikovaný online v októbrovom čísle Molecular Therapy.
